Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sees Unusually-High Trading Volume – Here’s What Happened

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) saw strong trading volume on Tuesday . Approximately 504,555 shares traded hands during mid-day trading, an increase of 195% from the previous session’s volume of 171,004 shares.The stock last traded at $27.00 and had previously closed at $26.71.

Analyst Upgrades and Downgrades

LKFT has been the topic of a number of research analyst reports. TD Cowen initiated coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, August 21st. They issued a “buy” rating on the stock. Morgan Stanley lowered their price objective on Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 11th. Royal Bank Of Canada cut their price target on Lakefront Biotherapeutics American Depositary Shares from $28.00 to $26.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Finally, Zacks Research raised Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Lakefront Biotherapeutics American Depositary Shares currently has a consensus rating of “Hold” and an average price target of $30.67.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -19.52 and a beta of 0.28. The business has a fifty day simple moving average of $28.27 and a 200 day simple moving average of $29.01.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its quarterly earnings results on Monday, August 10th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.97) by $1.01. The business had revenue of $15.47 million during the quarter, compared to analyst estimates of $7.29 million. On average, equities research analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -1.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Madison Avenue Partners LP boosted its holdings in Lakefront Biotherapeutics American Depositary Shares by 0.8% in the fourth quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock worth $72,371,000 after purchasing an additional 17,394 shares during the period. QRG Capital Management Inc. raised its stake in Lakefront Biotherapeutics American Depositary Shares by 21.9% during the 1st quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock valued at $591,000 after acquiring an additional 3,535 shares in the last quarter. ABC Arbitrage SA bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the first quarter valued at about $382,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the 1st quarter worth approximately $248,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.